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ABSTRACT 
Background: Diabetes mellitus and hypertension are aggravated by activa- 
tion of the renin-angiotensin ystem caused by increased oxygen stress and lo- 
cal inflammatory esponses. Several studies have suggested that angiotensin II 
type 1 receptors can reduce inflammatory markers (high-sensitivity C-reactive pro- 
tein [hs-CRP], interleukin [IL]-6, IL-18, soluble vascular cell adhesion molecule 
[VCAM]-I, and L-selectin) and oxidative stress markers (urinary 8-hydroxy-7,8- 
dihydro-2'-deoxyguanosine [8-OHdG] and 8-epi-prostaglandin F2c ~ [8-isoprostane]) 
in hypertensive patients. 
Objective: The aim of this study was to assess the effects of valsartan, an 
angiotensin II receptor blocker, on inflammatory and oxidative stress markers 
in hypertensive patients with mild diabetes or impaired glucose tolerance. 
Methods: In this open-label, prospective study, hypertensive patients aged 
>20 years with mild diabetes (requiring treatment by diet alone or an oral hypo- 
glycemic), seen on an outpatient basis at the Division of Diabetes, Metabolism, 
and Endocrinology, Omori Hospital, Toyko, Japan, who were receiving a thera- 
peutic dietary regimen for >1 month in the treatment of diabetes or hyperten- 
sion, were eligible for enrollment. Blood pressure, inflammatory markers (hs- 
CRP, IL-6, IL-18, VCAM-1, and L-selectin), and oxidative stress markers (urinary 
8-OHdG and 8-isoprostane) were monitored before treatment commencement 
with valsartan (40-80 mg/d) and after 3 months of treatment. 
Results: A total of 26 patients (18 men, 8 women; mean [SD] age, 57.7 
[11.3] years; mean [SD] weight, 65.3 [13.1] kg) were enrolled in the study. After 
3 months of treatment, patients' mean (SD) blood pressure had significantly 
decreased from 153.1 (11.2)/88.3 (11.4) to 143.7 (13.7)/85.2 (9.0) mm Hg (P < 
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0.05). Among the inflammatory and oxidative stress markers, hs-CRP, VCAM-1, 
and urinary 8-OHdG concentrations decreased significantly from 0.231 (0.199) 
to 0.134 (0.111) mg/dL (P = 0.043), 471.1 (193.9) to 403.2 (135.2) ng/mL (P = 0.012), 
and 12.12 (5.99) to 8.07 (3.36) ng/mg • creatinine (P = 0.001), respectively. The 
reductions in these markers were observed in patients regardless of whether 
or not their glycosylated hemoglobin (HbAI~) concentration improved (defined 
as a decrease of >1% in HbAI~ ). 
Conclusion: This small, open-label, prospective study found that a 3-month 
treatment with valsartan was associated with a significant reduction of hs-CRP, 
VCAM-1, and urinary 8-OHdG concentrations independent of improvement in
HbAlc concentration i  these hypertensive patients with hyperglycemia. (Curt 
Ther Res Clin Exp. 2007;68:338-348) Copyright © 2007 Excerpta Medica, Inc. 
Key words: valsartan, hypertension, diabetes, inflammatory marker, oxida- 
tive stress marker. 
INTRODUCTION 
Hypertension is a risk factor for cardiovascular diseases and frequently devel- 
ops concurrently with other risk factors, namely, visceral obesity, insulin 
resistance, glucose intolerance, and abnormal lipid metabolism. 1 Because these 
disorders are believed to be associated with closely related factors, together 
they are regarded as metabolic syndrome. 2,3 
Numerous clinical trials 4,5 have found that treatment of hypertension can 
prevent he onset of cardiovascular diseases. The guidelines from the Japanese 
Society of Hypertension 6 recommend aggressive antihypertensive treatment. 
Because tiologic studies 7 of hypertension have demonstrated that activation of 
the renin-angiotensin (RA) system contributes to the maintenance of high blood 
pressure or the onset of cardiovascular diseases associated with hypertension, 
interest in the clinical significance of RA system inhibitors has been increasing. 
As the relationship between angiotensin II receptors and insulin resistance as 
well as the roles of genes in glucose metabolism are also becoming more 
evident, 89 there is increasing interest in both the antihypertensive effects of RA 
system inhibitors and their beneficial effects on carbohydrate metabolism. 
Meanwhile, local inflammation has been identified as an etiologic factor for 
the onset of cardiovascular diseases, 1°and in vitro studies 11 have found that 
stimulation of angiotensin II receptors accelerates the generation of free radi- 
cals and the release of inflammatory cytokines. Thus, hypertension may con- 
tribute to increases in the incidence of cardiovascular diseases, not only by 
imposing a load on the cardiovascular system, but also by promoting cardio- 
vascular inflammation and/or affecting carbohydrate metabolism. Several 
reports have already found that angiotensin II receptor blockers (ARBs) signifi- 
cantly suppress inflammatory and oxidative stress markers, including high- 
sensitivity C-reactive protein (hs-CRP), monocyte chemoattractant protein 1, 
interleukin (IL)-6, and urinary 8-epi-prostaglandin F2~ (8-isoprostane). 12-14 
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Therefore, we focused on the physiologic activity of angiotensin II and exam- 
ined the effects of valsartan, an ARB, on inflammatory markers and markers of 
oxidative stress in hypertension complicated by mild diabetes or impaired glu- 
cose tolerance. 
PATIENTS AND METHODS 
Among hypertensive outpatients at the Division of Diabetes, Metabolism, and 
Endocrinology, Omori Hospital, Tokyo, Japan, patients aged >20 years who had 
been receiving dietary treatment for diabetes or hypertension for >1 month and 
had a blood pressure >140/90 mm Hg (mean of 3 measurements at outpatient 
clinic) were enrolled in this study, regardless of whether they were receiving 
antihypertensive tr atment. Diabetic patients also participated in the study, 
but only those with mild diabetes (glycosylated hemoglobin [HbAlc ] <9.0% and 
treated by diet alone or an oral hypoglycemic agent) were selected. Patients 
with a serum creatinine concentration >1.5 mg/dL were excluded. 
All study protocols and procedures were approved by the Ethics Committee 
of Toho University Medical Center. The study objectives and intended mea- 
sures were explained to 27 prospective study patients (individually), and 26 pa- 
tients completed the study (1 patient discontinued the treatment). Written 
informed consent was obtained from all patients. Valsartan* was administered 
at doses of 40 to 80 mg/d. The initial dose of valsartan was 40 mg/d, and the 
dose was increased to 80 mg/d after 1 month if the systolic and diastolic blood 
pressures were still >140 and/or 90 mm Hg, respectively. Inflammatory mark- 
ers (hs-CRP, IL-6, IL-18, soluble vascular cell adhesion molecule [VCAM]-I, 
and L-selectin) and oxidative stress markers (8-hydroxy-7,8-dihydro-2'- 
deoxyguanosine [8-OHdG] and 8-isoprostane) were measured before the start 
of drug administration a d also after 3 months of treatment. All hypolipidemic, 
hypoglycemic, and/or antihypertensive drugs already being administered were 
continued without any changes in their dosage or mode of administration. 
Dietary and exercise treatments were also continued, and the patients were 
advised not to change their current lifestyles. 
While in supine position, the patients' height, body weight, and blood pres- 
sure (left arm) were measured and recorded at each visit. Blood samples were 
drawn in the morning after an overnight fast before and after 3 months of val- 
sartan treatment. The blood samples were collected into tubes containing 
ethylenediaminetetraacetic acid (1.5 g/L) and centrifuged at 1000g for 20 min- 
utes at 4°C to obtain plasma. Concentrations of total cholesterol, triglycerides, 
high-density lipoprotein cholesterol, and serum creatinine were measured 
using an autoanalyzer. HbAlc was measured using high-pressure liquid chroma- 
tography, while hs-CRP was measured by the method of Ledue et al. 15 IL-6 
(Quantikine HS human IL-6 kit, R&D Systems Inc., Minneapolis, Minnesota), 
*Trademark: Diovan ® (Novartis Pharma AG, Basel, Switzerland). 
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IL-18 (Human IL-18 ELISA kit, MBL Co., Nagoya, Japan), VCAM-1 (Quantikine 
human sVCAM-1 kit, R&D Systems Inc.), and L-selectin (human sL-Selectin kit, 
R&D Systems Inc.) were measured by enzyme-linked immunosorbent assays 
(ELISAs) using the cited kits, while the urinary oxidative stress markers 
8-OHdG 16 and 8-isoprostane 17 were measured by ELISA and enzyme immunoas- 
say, respectively. To monitor the adverse ffects (AEs) possibly associated with 
valsartan, clinical symptoms (eg, headache, nausea, stomachache, muscle 
pain) were assessed by observation at each visit, and routine biochemical 
analyses (aspartate aminotransferase, alanine aminotransferase, 7-glutamyl 
transpeptidase, uric acid, creatinine, sodium, potassium, chloride, calcium, 
phosphorus, and lactate dehydrogenase) were performed simultaneously. 
Statistical Analysis 
Data are expressed as mean (SD), and the data before and after valsartan 
administration were compared using a paired t test. 
RESULTS 
Table I illustrates the baseline demographic and clinical characteristics of the 
26 patients (18 men, 8 women; mean [SD] age, 57.7 [11.3] years; mean [SD] 
weight, 65.3 [13.1] kg) enrolled in the study. Type 2 diabetes was detected in 
20 (76.9%) patients, hyperlipidemia in 17 (65.4%), glucose intolerance in 
6 (23.1%), and hyperuricemia in 2 (7.7%). Nine (34.6%) patients were receiving 
concomitant treatment with statins. The hypoglycemic drugs used were sulfonyl- 
urea compounds in 3 (11.5%) patients and c¢-glucosidase inhibitors in 2 (7.7%) pa- 
tients. The antihypertensive drugs used were a calcium channel blocker (CCB) in 
4 (15.4%) patients and a [3-blocker in 1 (3.8%) patient, who was also treated with 
a CCB. 
In 17 (65.4%) patients, body mass index (BMI) was >25 kg/m 2 before the ad- 
ministration of valsartan. Blood pressure decreased significantly from 153.1 
(11.2)/88.3 (11.4) mm Hg at baseline to 143.7 (13.7)/85.2 (9.0) mm Hg (P < 0.05) 
after 3 months of valsartan treatment. However, when the patients were evalu- 
ated by CCB use, only systolic blood pressure showed a significant decrease 
(P < 0.05) in non-CCB users (n = 22). 
Table II illustrates the changes in indicators of lipid and blood glucose con- 
trol after 3 months of valsartan treatment. No significant changes were detected 
in these indicators, with the exception of HbAlc concentration, which decreased 
from mean (SD) 7.05% (1.47%) to 6.52% (1.04%) (P = 0.007). HbAlc improved 
(defined as a decrease of >1%) in 5 (19.2%) patients, while it increased in 
8 (30.8%) patients. Serum creatinine concentration i creased from 0.77 (0.22) 
to 0.80 (0.27) mg/dL, but this difference was not significant. 
Table III illustrates the changes in inflammatory and oxidative stress mark- 
ers after valsartan treatment. Among the 7 measured markers, hs-CRP 
decreased significantly from 0.231 (0.199) to 0.134 (0.111) mg/dL (P = 0.043). 
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Table I. Baseline demographic and clinical characteristics of patients 
(N = 26) in the open-label, prospective study on the effects 
of valsartan on inflammatory and oxidative stress markers 
in hypertensive patients. 
Characteristic Value 
Age, mean (SD), y 57.7 (11.3) 
Sex, no. 
Male 18 
Female 8 
Weight, mean (SD), kg 65.3 (13.1) 
Concurrent disease, no. (%) 
Type 2 diabetes 20 (76.9) 
Hyperlipidemia 17 (65.4) 
Impaired glucose tolerance 6 (23.1) 
Hyperuricemia 2 (7.7) 
Concomitant drugs, no. (%) 
Hypolipidemic 
Statins 9 (34.6) 
Hypoglycemic 
Sulfonylurea 3 (11.5) 
c~-Glucosidase inhibitor 2 (7.7) 
Anti hypertensive 
Calcium channel blocker 4 (15.4) 
13-Blocker 1 (3.8) 
Table II. Changes in the states of lipid and blood glucose control in the open-label, 
prospective study on the effects of valsartan on inflammatory and oxida- 
tive stress markers in hypertensive patients. Data are mean (SD). 
Before Valsartan After Valsartan 
Treatment Treatment P* 
Total cholesterol, mg/dL 
HDL-cholesterol, mg/dL 
Triglycerides, mg/dL 
Fasting blood glucose, mg/dL 
HbAlc, % 
215.6 (61.2) 207.5 (39.4) 0.351 
52.0 (11.0) 56.3 (20.7) 0.276 
148.4 (83.0) 155.3 (93.8) 0.594 
151.7 (53.2) 140.8 (40.3) 0.234 
7.05 (1.47) 6.52 (1.04) 0.007 
HDL = high-density lipoprotein; HbAlc = glycosylated hemoglobin. 
*Determined by paired t test. 
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Table III. Changes in inflammatory and oxidative stress markers in the open-label, 
prospective study on the effects of valsartan on inflammatory and oxida- 
tive stress markers in hypertensive patients. Data are mean (SD). 
Before Valsartan After Valsartan 
Treatment Treatment P* 
hs-CRP, mg/dL 0.231 (0.199) 0.134 (0.111) 0.043 
IL-6, pg/mL 7.11 (7.88) 10.36 (16.86) 0.328 
IL-18, pg/mL 241.1 (134.3) 236.7 (114.5) 0.769 
VCAM-1, ng/mL 471.1 (193.9) 403.2 (135.2) 0.012 
L-Selectin, ng/mL 849.8 (198.4) 864.8 (279.7) 0.743 
8-1soprostane, pg/mg • Cr 283.5 (101.5) 302.0 (151.6) 0.559 
8-OHclG, ng/mg • Cr 12.12 (5.99) 8.07 (3.36) 0.001 
hs-CRP = high-sensitivity C-reactive protein; IL = interleukin; VCAM-1 = vascular cell adhesion 
molecule; 8-isoprostane = 8-epi-prostaglandin F2~; Cr = creatinine; 8-©HdG = 8-hydroxy-7,8- 
dihydro-2'-deoxyguanosine. 
*Determined by paired t test. 
VCAM-1 and urinary 8-OHdG also decreased significantly from 471.1 (193.9) to 
403.2 (135.2) ng/mL (P = 0.012) and from 12.12 (5.99) to 8.07 (3.36) ng/mg • creati- 
nine (Cr) (P = 0.001), respectively. The decrease in urinary 8-OHdG concentra- 
tion remained significant (P < 0.05) when the patients were divided into 2 co- 
horts: CCB users (n = 4) and non-CCB users (n = 22). After grouping the patients 
according to statin use, the decrease in urinary 8-OHdG concentration remained 
significant (P < 0.05) in both statin users (n = 9) and nonstatin users (n = 17), 
while hs-CRP concentration did not show a significant change in either group. 
Concentrations of IL-6, IL-18, L-selectin, and 8-isoprostane did not change sig- 
nificantly after 3 months of treatment. 
Analysis of the relationships of markers that exhibited statistically signifi- 
cant changes with HbAlc concentration revealed that hs-CRP, VCAM-1, and 
urinary 8-OHdG concentrations decreased regardless of whether or not HbAlc 
showed improvement (Figure). In patients who showed no improvement of 
HbAI~ (increase or no change), VCAM-1 and 8-OHdG concentrations decreased 
significantly from 464.9 (210.3) to 400.5 (131.5) ng/mL (P < 0.05) and from 11.53 
(5.78) to 7.70 (3.63) ng/mg • Cr (P < 0.01), respectively. Furthermore, 8-OHdG 
concentration decreased significantly from 9.26 (3.93) to 6.56 (2.26) ng/mg • Cr 
(P < 0.05) in patients whose HbAI~ improved. In 13 patients with a BMI of >25% 
who were considered to have metabolic syndrome based on the presence of 
hypertension and diabetes or glucose intolerance, hs-CRP concentration de- 
creased significantly from 0.182 (0.188) to 0.114 (0.118) mg/dL (P < 0.05), while 
VCAM-1 and 8-OHdG concentrations decreased significantly from 506.3 (220.8) 
to 419.8 (142.5) ng/mL (P < 0.05) and from 12.18 (4.95) to 7.71 (2.56) ng/mg • Cr 
(P < 0.05), respectively. 
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Figure. Changes in high-sensitivity C-reactive protein (hs-CRP), urinary 8-hydroxy- 
7,8-dihydro-2Ldeoxyguanosine (8-OHdG), and soluble vascular cell adhesion 
molecule (VCAM-1) concentrations after valsartan therapy. Dotted lines 
represent the data of patients who exhibited improvement in glycosylated 
hemoglobin (HbAlc) concentration (defined as a decrease of _>1% in HbAlc ). 
Vertical lines represent the mean (SD). Cr -- creatinine. The P values in 
figure are before versus after valsartan treatment. *P = 0.043; tp = 0.001; 
~P = 0.012. 
During the observation period, no AEs (including the occurrence of the clinical 
symptoms and changes in the biochemical parameters studied) were detected. 
DISCUSSION 
In this study, t reatment with valsartan for 3 months was associated with signifi- 
cant decreases in 3 (hs-CRP, VCAM-1, and 8-OHdG) of the 7 inf lammatory and 
oxidative stress markers examined in hypertensive patients with mild diabetes 
or glucose intolerance. Decreases in these markers were detected in obese 
patients with a BMI >25%, which might suggest he clinical utility of valsartan 
as a therapeutic agent for metabolic syndrome. 
It has been scientifically established that increased concentrat ions of hs- 
CRP are associated with incident hypertension and cardiovascular events. 18,19 
The suppression of hs-CRP by valsartan demonstrated in this study is consis- 
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tent with previous reports.  2°-22 It has been suggested that vascular inflamma- 
tion regulated in part  by the RA system and antagonism of angiotensin II might 
modulate the atherosclerotic process. 23 Recently, CRP has been found to upregu- 
late angiotensin II receptors.  24 Therefore, it is possible that valsartan blocks 
angiotensin II receptors,  thereby suppressing vascular inflammation. 
ILs are inf lammatory cytokines secreted by activated monocytes  or mac- 
rophages. They promote the cell membrane express ions of VCAM-1 and 
L-selectin, which are molecules in monocyte adhesion to the vascular endothe- 
lium. 11 Secretion of these inf lammatory cytokines is accelerated by oxidative 
stress, while angiotensin II increases oxidative stress through the activation 
and induction of nicotinamide adenine dinucleotide phosphate hydrogen 
(NADPH). 25 In this study, hs-CRP as well as the adhesion molecule VCAM-1 and 
ur inary 8-OHdG were significantly reduced after valsartan treatment. These 
findings suggest he possibil ity that valsartan blocks angiotensin II receptors in 
vascular tissues, which may suppress both inf lammatory and oxidative stress 
markers. Because CRP is not only an inf lammatory marker but also exacerbates 
inflammation and induces vascular endothelial adhesion factor expression, 26 it 
seems reasonable that serum VCAM-1 concentrat ion should have decreased 
after valsartan treatment.  
Of the 2 oxidative stress markers measured in this study, ur inary 8- 
isoprostane concentrat ion showed no significant change, whereas ur inary 
8-OHdG concentrat ion was significantly reduced in the cohort  that received 
valsartan treatment. The former is a metabolite of arachidonic acid, which is 
cleaved from the phospholipid moiety by phosphol ipase A2, and seems to be 
generated by the direct action of active oxygen on the phospholipid moiety, 
unlike other prostaglandins formed through the ordinary pathway mediated by 
a synthetic enzyme (cyclooxygenase). 16 The latter is an oxide of the 8th posi- 
tion of the guanine molecule that constitutes DNA and is a subject of ongoing 
studies, both as an oxidative stress marker and as a substance that induces 
DNA mutations. 17Since NADPH activated or promoted by angiotensin II is pres- 
ent on the cell membrane, it was expected that valsartan would act more readi- 
ly on 8-isoprostane production. However, in this study, 8-OHdG was more 
strongly affected by valsartan than 8-isoprostane, which may be attr ibuted to 
differences in the effects of valsartan that depend on the type of active oxygen 
or whether the active oxygen was close to the cell membrane or around the 
nucleus. However, no studies have yet focused on the differences in the oxida- 
tive processes between the 2 markers, and it is difficult to clarify differences in 
the mechanisms of oxidation in clinical settings (as with this current study). 
Nevertheless, the present findings are interesting from the viewpoint of studies 
on the mechanisms of action of oxidative stress. Whatever the mechanism, 
valsartan treatment produced a decrease in ur inary 8-OHdG concentrat ion i
patients who did not show a decrease in HbAlc concentration, suggesting the 
possibility that valsartan might suppress not only inflammation but also oxida- 
tive stress independently of glucose metabolism. 
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Metabolic syndrome is defined as the concurrent presence of visceral obesity, 
glucose intolerance, abnormal ipid metabolism, and hypertension. The inci- 
dence rate of cardiovascular disorders is known to be high in such patients. 2,3 
However, since metabolic syndrome is a concept hat includes the prodromal 
state of a definitive disease, its treatment is controversial. An aspect hat is com- 
monly accepted as a pathophysiologic process is the release of inflammatory 
cytokines or angiotensinogen from adipocytes, and the insulin resistance medi- 
ated by such molecules may be a stimulatory factor for the development of car- 
diovascular diseases, including hypertension. Since this suggests that the secre- 
tion of inflammatory cytokines induced by oxidative stress is the mechanism by 
which such a pathologic process develops, it would be desirable to aggressively 
use RA inhibitory drugs if a patient has abnormal glucose metabolism, abnormal 
lipid metabolism, needs therapy for hypertension, and is considered to have 
metabolic syndrome. In this study, valsartan produced significant decreases in 
oxidative stress markers and adhesion factors in patients considered to have 
metabolic syndrome, suggesting the clinical usefulness of valsartan. 
Because we did not have a control group of patients treated with an antihyper- 
tensive agent hat does not affect he RA system, it is possible that the reduction 
in blood pressure alone may have resulted in the decreases in oxidative stress and 
inflammatory markers. However, a previous tudy 13 reported a blood pressure- 
independent effect of valsartan on an oxidative stress marker in patients with 
type 2 diabetes, as evaluated by measuring plasma thiobarbituric acid-reactive 
substances. Therefore, the reduction in oxidative stress observed in this study 
could possibly be explained by valsartan. In the Valsartan Antihypertensive Long- 
term Use Evaluation trial 27 involving high-risk hypertensive patients, valsartan 
reduced the incidence of diabetes by 23% compared with the reference drug 
amlodipine, suggesting the clinical significance of RA system inhibitors. Among 
the 26 patients enrolled in this study, HbAlc improved in 6 patients. Valsartan has 
been reported to improve insulin resistance in experimental models, 8but this has 
not yet been confirmed clinically. Although it remains unclear whether the pres- 
ent results were produced by the aforesaid mechanism of action of valsartan, our 
findings warrant further clinical investigation. 
Limitations 
This was a small, open-label, prospective study, and some of the enrolled 
patients were already receiving statins and/or other hypotensive drugs other 
than valsartan. Additionally, the observation period was only 3 months, and 
long-term prognosis remains unclear. The results of ongoing clinical studies 28,29 
in Japan are awaiting. 
CONCLUSION 
Valsartan use for 3 months was associated with a significant reduction of hs- 
CRP, VCAM-1, and urinary 8-OHdG concentrations independent of improvement 
346 
K. Kuboki et al. 
in HbAlc concentration i these hypertensive patients with hyperglycemia n- 
cluded in this small, open-label, prospective study. 
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